The health authorities in the country have adopted several options to treat children infected with the Corona virus, so that each case is treated separately, after consulting with a specialist, and obtaining approval from the patient to treat the infection, or from his family if he is not qualified.
According to the National Guidelines for Management and Treatment of Covid-19 cases in the country, the therapeutic dose for children is determined according to a solution of chloroquine phosphate salt, and not on the basis of chloroquine baseline. Interferon should not be a routine option for all ICU patients, except in cases Very rare, based on a risk assessment of the benefits to be derived from it.
The evidence stressed that the preferred approach to treatment should be to start using other Covid-19 drugs, without rushing to give the patient interferon, and to monitor the patient in anticipation of a so-called “cytokine storm”, and if his condition accepts taking the drug « Tosselzumab "can take" only two doses, or three doses in rare cases, and the third dose may be taken after a comprehensive evaluation of the patient's response.
She emphasized that the patient should stop taking Interferon if he takes it regularly, and then start taking Tocelzumab, and that there should be an interval of between 24 and 48 hours, after the last dose of the drug Interferon, and the patient should not return to take Interferon after taking Tossilzumab.
The guide identified several guidelines for the use of the drug «Tossilzumab» for children under two years in intensive care, as the drug is currently being researched, for use in the treatment of patients with complications of pneumonia associated with the Corona virus, and the safety and efficacy associated with it have not yet been established. (Commercial formula IV should be used only, with no pre-filled Sub-Q syringes.) It is used only for infectious disease doctors, intensive care physicians only, and for COVID-19 patients with severe shortness of breath after the failure of the first treatment method.
According to the evidence, "If the child in the intensive care unit suffers from severe shortness of breath, the possibility of developing a" cytokine storm ", and a candidate to take the drug (Tocelzumab), he should not start giving him the drug" interferon "because he may have severe side effects associated with two modified immunomodulatory drugs. They are “Tossilzumab” and “Interforn.”
Usage data for the drug "faviravir"
According to the national guidelines for managing and treating "Covid-19" cases in the country, there is no data or information available on the use of the drug "faviravir" known as "Avicane", for children aged 12 months or more, and weighing 10 kg or more, as The dosage system was derived based on the pharmacological dosage regimens and the single dose method, from the doses used in the Ebola trial in 12 children, less than 12 months of age and their body weights less than 10 kg, the dose is 50% lower, and the support dose is 25% lower compared to a dose Ebola, on an almost identical scale, could adopt the same strategy Children also have to reduce the dose.
Interferon is a routine option for all ICU patients except in very rare cases.